Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Vera Therapeutics, Inc.VERA · Entity 4358 | Chief Legal Officer | November 21, 2025 | November 25, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Vera Therapeutics, Inc.
Report date November 21, 2025 · Filed November 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 49,136 |
Reported balance
After 2025-11-21 transaction · row 1
1 source rowRow 1 · 2025-11-21 · Sale · Disposed 3,864 · Balance 49,136 F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.19 to $28.035, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units.
F2: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.19 to $28.035, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 21, 2025 Filed Nov 25, 2025 16:05 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | SaleClass A Common Stock | 3,864 | $27.82 | $107,498.03 |
DisclosureSEC source: 0001193125-25-297161 · ownership.xml · nonDerivative · entry 1 Carter Jason S · CIK 0002045094 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,136 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. F2 · price: The price reported is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.19 to $28.035, inclusive. The Reporting Person will provide upon request to the staff of the Securities and Exchange Commission, the Issuer or any security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 16:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 108,000 | $0.00 Strike: $44.81 | $0.00 |
DisclosureSEC source: 0001415889-24-027332 · form4-11202024_091116.xml · derivative · entry 2 Carter Jason S · CIK 0002045094 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,000 Underlying: Class A Common Stock · 108,000 shares Expires 2034-11-17 F2 · derivative.exercise_date: 1/4 of the shares subject to the option vest on November 18, 2025, and 1/48 of the shares vest monthly thereafter, subject to continuous service of the Reporting Person through each vesting date. Read SEC document |
| November 18, 2024 Filed Nov 20, 2024 16:07 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantClass A Common Stock | 53,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-027332 · form4-11202024_091116.xml · nonDerivative · entry 1 Carter Jason S · CIK 0002045094 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,000 F1 · shares: Represents the number of shares of Class A Common Stock underlying the restricted stock units ("RSUs") under the Issuer's 2024 Inducement Plan. One-fourth of the RSUs vest on each February 20, May 20, August 20 and November 20 following the vesting commencement date of November 18, 2024, subject to the Reporting Person's continuous service through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.